Pharmaceutical Sector Tax Guide Pakistan — Manufacturing vs Distribution

A pharmaceutical manufacturer and a pharmaceutical distributor sit at genuinely different points in the same regulated supply chain, and while both benefit from the sector's broadly favorable sales tax treatment on medicines, the practical tax mechanics each actually faces — depreciation on manufacturing plant, distribution margin treatment, DRAP-linked compliance — differ meaningfully between the two.

A Sector Built Around a Genuinely Significant Sales Tax Exemption

Pakistan's pharmaceutical sector genuinely operates within a distinctive, sector-defining tax framework anchored specifically by the Sixth Schedule to the Sales Tax Act, under which medicines are generally exempt from sales tax — a genuinely significant exemption given that sales tax applies to most locally produced and imported goods by default. This exemption shapes how both manufacturers and distributors in the sector actually operate, though the exemption's precise scope and any related import-side charges have been subject to active discussion and potential revision in recent budget cycles.

Manufacturer-Specific Tax Considerations

A pharmaceutical manufacturer genuinely operates a capital-intensive business by nature — production facilities, specialized manufacturing equipment, quality-control laboratory equipment, and dedicated cold-chain storage for temperature-sensitive products — all of which are depreciable business assets under standard income tax depreciation rules, with plant and machinery generally depreciated over time and eligible for an initial allowance in the year first placed into service. A manufacturer should maintain a thorough, organized fixed-asset register tracking this capital investment carefully, given how genuinely significant depreciation can be as a deduction against a manufacturer's taxable income relative to a comparatively asset-light distribution business.

DRAP Licensing — Separate From, But Relevant to, Tax Compliance

Pharmaceutical manufacturing and distribution activity in Pakistan genuinely requires proper licensing from the Drug Regulatory Authority of Pakistan (DRAP), a regulatory requirement entirely separate from FBR tax registration but relevant to a pharmaceutical business's overall compliance picture. A pharmaceutical business should sequence its registrations correctly when setting up or expanding operations — DRAP licensing for the underlying regulated activity, alongside standard FBR income tax and any applicable sales tax registration — rather than assuming one registration covers the other, since these represent genuinely distinct regulatory tracks a pharmaceutical business needs to satisfy simultaneously.

Imported Finished Pharmaceutical Products — A Genuinely Active Policy Area

Beyond the core medicine sales tax exemption, imported finished pharmaceutical and diagnostic products have quite specifically faced additional charges under separate schedules at various different points, with active discussion around reducing or removing these specific charges to lower production and healthcare costs. A pharmaceutical business genuinely importing finished products, active pharmaceutical ingredients, or diagnostic kits should carefully confirm the current specific treatment of these imports directly and explicitly, given how genuinely active and unsettled this particular policy area has actually been across recent budget cycles — an assumption simply carried forward from an earlier year's treatment risks being genuinely outdated by now.

Distributor-Specific Tax Considerations

A pharmaceutical distributor operates a genuinely different business model from a manufacturer — buying finished medicines from manufacturers and reselling through a distribution network to pharmacies, hospitals, and retail outlets, earning a margin on this distribution activity rather than generating manufacturing profit directly. A distributor's taxable income is genuinely calculated on this margin-based business model, with real business expenses — warehousing, transport and logistics, sales staff, and distribution infrastructure — deductible against gross distribution revenue, following the same standard business income principles applied to comparable margin-based distribution businesses rather than the specific manufacturing-related depreciation considerations covered above.

Withholding Tax Considerations Across the Supply Chain

Payments genuinely flowing through the pharmaceutical supply chain — a distributor paying a manufacturer, a pharmacy or hospital paying a distributor — can genuinely attract withholding tax under the applicable provisions, depending on the specific relationship and payer classification actually involved in each case, following the general withholding framework covered elsewhere on this site for supply and services transactions. A pharmaceutical business at any given point in this chain should carefully confirm its own specific withholding obligations — both as a payer required to withhold on payments actually made, and as a recipient whose own receipts might separately be subject to withholding by others — since a capital-intensive, multi-tier supply chain like the pharmaceutical sector genuinely involves multiple distinct withholding relationships all running simultaneously.

Where the Medicine Exemption Doesn't Automatically Extend

It's genuinely worth being clear that the Sixth Schedule medicine exemption applies specifically and narrowly to qualifying medicines themselves, and a pharmaceutical business with adjacent product lines — cosmetics, supplements, or medical devices that don't actually qualify as medicines under the specific schedule definition — shouldn't simply assume these adjacent products automatically carry the exact same sales tax exemption. A business genuinely running a mixed product portfolio should get each specific product line's sales tax classification confirmed individually and carefully, rather than simply assuming blanket exemption across the entire portfolio just because the overall business is broadly "pharmaceutical" in nature.

Research, Development, and Regulatory Approval Costs

A pharmaceutical manufacturer investing in research and development, or in the regulatory approval process for new products through DRAP, incurs genuine costs specific to this sector — clinical or bioequivalence study costs, regulatory filing and approval costs, and related specialized expenses — which are deductible business expenses against the manufacturer's taxable income, tracked separately from standard production and distribution costs. A manufacturer genuinely running an active product development pipeline should carefully maintain clear, organized records of these specific R&D and regulatory costs, given how genuinely significant this particular expense category can actually be for a manufacturer actively expanding its overall product range over time.

Charitable Hospital Sales — A Distinct, Narrower Exemption

Beyond the general medicine exemption, a separate, genuinely narrower sales tax exemption applies specifically and only to charitable hospitals under its own distinct schedule entry, worth understanding clearly as genuinely separate from the broader medicine exemption covered throughout the rest of this guide. A pharmaceutical business genuinely supplying to charitable hospitals specifically should carefully confirm whether this narrower, hospital-specific provision actually applies to their particular transaction, rather than simply assuming the general medicine exemption and any charitable-hospital-specific provision are entirely interchangeable with one another.

Contract Manufacturing Arrangements

Some pharmaceutical companies operate under contract manufacturing arrangements, where one company (the principal, often holding the brand and marketing rights) engages another company's manufacturing facility to actually produce the medicine under a toll manufacturing or contract manufacturing agreement. Both parties involved in this kind of arrangement genuinely have their own separate, entirely distinct tax obligations — the contract manufacturer declares the manufacturing fee it earns as its own revenue, deducting its own production costs against that fee income, while the principal declares its own separate revenue from ultimately selling the finished product, deducting the contract manufacturing fee paid as its own business expense. A pharmaceutical company genuinely entering a contract manufacturing relationship for the first time should get this specific revenue-and-expense split confirmed clearly and explicitly within the underlying written agreement, since an unclear split between the two parties can genuinely create real ambiguity about which side is actually responsible for which specific tax treatment.

Pharmaceutical Exports and Related Considerations

A pharmaceutical manufacturer with a genuine, meaningful export component to its overall business — supplying finished medicines or active pharmaceutical ingredients out to foreign markets — should layer standard exporter tax treatment covered elsewhere on this site on top of the sector-specific considerations covered throughout this guide, since export income follows its own distinct treatment separate from the domestic medicine-exemption framework. A manufacturer genuinely running a mixed domestic-and-export sales profile should keep these two revenue streams clearly and carefully distinguished within its own records, since domestic medicine sales benefit from the Sixth Schedule sales tax exemption in a way that doesn't necessarily carry over identically to the separate tax mechanics genuinely applicable to export sales specifically.

Common Mistakes

• Assuming all pharmaceutical-adjacent products (cosmetics, supplements, devices) share the medicine exemption: confirm each specific product line's classification individually.
• Not maintaining a thorough fixed-asset register for manufacturing plant and equipment: depreciation can be a genuinely significant deduction for capital-intensive manufacturers.
• Assuming DRAP licensing satisfies FBR tax registration requirements or vice versa: these are separate, distinct regulatory tracks requiring separate compliance.
• Relying on outdated treatment of imported finished pharmaceutical products: this has been a genuinely active area of budget-cycle discussion and revision.
• Not tracking R&D and regulatory approval costs as their own deductible expense category: these can be genuinely significant for manufacturers actively developing new products.

A Worked Example

A pharmaceutical manufacturer maintains a detailed fixed-asset register tracking its production facility, manufacturing equipment, and laboratory instruments, correctly applying depreciation and available initial allowances against its taxable manufacturing income each year. The manufacturer confirms its core medicine products qualify for the Sixth Schedule sales tax exemption, while separately confirming the sales tax treatment of a newly launched supplement product line, recognizing supplements may not automatically qualify under the same medicine-specific exemption. Its distribution partner, genuinely operating on a margin-based model, carefully deducts its own warehousing, logistics, and sales-staff costs against distribution revenue, while both businesses carefully confirm their respective withholding obligations toward each other and toward the pharmacies and hospitals further down the overall supply chain.

Frequently Asked Questions